Pathophysiology and treatment of hot flashes

Mayo Clinic Proceedings

Volumn 77, Issue 11, 2002, Pages 1207-1218

  Shanafelt, Tait D ^a   Barton, Debra L ^a   Adjei, Alex A ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA TOCOPHEROL; ANDROGEN; ANTIDEPRESSANT AGENT; BELLADONNA ALKALOID; CLONIDINE; CORTICOSTEROID; DANAZOL; ESTROGEN; FLUOXETINE; GABAPENTIN; GESTAGEN; ISOFLAVONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHYLTESTOSTERONE; PAROXETINE; PHYTOESTROGEN; PLACEBO; PRASTERONE SULFATE; PROGESTERONE; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE BINDING GLOBULIN; SOYBEAN PROTEIN; TAMOXIFEN; TIBOLONE; UNINDEXED DRUG; VENLAFAXINE; VERALIPRIDE;

ADULT; AGED; ANOREXIA; ARTICLE; ATAXIA; BEHAVIOR MODIFICATION; BREAST CANCER; CANCER PATIENT; CANCER RISK; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DYSTONIA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FATIGUE; FEMALE; GALACTORRHEA; GASTROINTESTINAL TOXICITY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPOTHALAMUS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MODEL; NEUROTRANSMISSION; NYSTAGMUS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAXATION TRAINING; SIDE EFFECT; SOMNOLENCE; STRESS; TREATMENT OUTCOME; TREMOR; XEROSTOMIA;

EID: 0036843764     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.11.1207     Document Type: Article

References (112)

1. McKinlay SM, Jefferys M. The menopausal syndrome. Br J Prev Soc Med. 1974;28:108-115.
2. Roberts J, Chambers LF, Blake J, Webber C. Psychosocial adjustment in post-menopausal women. Can J Nurs Res. Winter 1992;24:29-46.
3. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ. 1993;307:836-840.
4. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999;353:571-580.
5. Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA. Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage. 1998;16:327-333.
6. Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage. 2000;19:436-445.
7. Koster A. Hormone replacement therapy: Use patterns in 51-yearold Danish women. Maturitas. 1990;12:345-356.
8. Rabin DS, Cipparrone N, Linn ES, Moen M. Why menopausal women do not want to take hormone replacement therapy. Menopause. Spring 1999;6:61-67.
9. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000;95:726-731.
10. Lobo RA, McCormick W, Singer F, Roy S. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol. 1984;63:1-5.
11. Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
12. Creasman WT. Estrogen and cancer. Gynecol Oncol. 2002;86:1-9.
13. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol. 2000;53:367-375.
14. Lacey JV Jr, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002;288:334-341.
15. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 2002;94:497-504.
16. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293:1167-1170.
17. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293:1164-1167.
18. McDonald TW, Malkasian GD, Gaffey TA. Endometrial cancer associated with feminizing ovarian tumor and polycystic ovarian disease. Obstet Gynecol. 1977;49:654-658.
19. Hoibraaten E, Qvigstad E, Amesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000;84:961-967.
20. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689-696.
21. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:58-66.
22. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001;345:1787-1793.
23. Heckbert SR, Kaplan RC, Weiss NS, et al, Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med. 2001;161:1709-1713.
24. Alexander KP, Newby LK, Hellkamp AS, et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol. 2001;38:1-7.
25. Hulley S, Grady D, Bush T, et al, Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
26. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
27. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA, Heart and Estrogen/progestin Replacement Study Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: Results from the Heart and Estrogen/progestin Replacement Study (HERS) trial. JAMA. 2002;287:591-597.
28. Vastag B. Hormone replacement therapy falls out of favor with expert committee. JAMA. 2002;287:1923-1924.
29. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734-741.
30. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis. Obstet Gynecol. 1998;92:472-479.
31. Berg G, Gottwall T, Hammar M, Lindgren R, Gottgall T. Climacteric symptoms among women aged 60-62 in Linkoping, Sweden, in 1986 [published correction appears in Maturitas. 1988;10:363]. Maturitas. 1988;10:193-199.
32. Carpenter JS, Andrykowski MA, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma: Prevalence, severity, correlates, management, and relation to quality of life. Cancer. 1998;82:1682-1691.
33. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842-1847.
34. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: An hypothesis of flush mechanism. Clin Endocrinol (Oxf). 1985;22:293-312.
35. Aksel S, Schomberg DW, Tyrey L, Hammond CB. Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause. Am J Obstet Gynecol. 1976;126:165-169.
36. Abe T, Furuhashi N, Yamaya Y, Wada Y, Hoshiai A, Suzuki M. Correlation between climacteric symptoms and serum levels of estradiol, progesterone, follicle-stimulating hormone, and luteinizing hormone. Am J Obstet Gynecol. 1977;129:65-67.
37. Chakravarti S, Collins WP, Newton JR, Oram DH, Studd JW. Endocrine changes and symptomatology after oophorectomy in premenopausal women. Br J Obstet Gynaecol. 1977;84:769-775.
38. Hutton JD, Jacobs HS, Murray MA, James VH. Relation between plasma oestrone and oestradiol and climacteric symptoms. Lancet. 1978;1:678-681.
39. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab. 1995;80:2354-2358.
40. Casper RF, Yen SS, Wilkes MM. Menopausal flushes: A neuroendocrine link with pulsatile luteninizing hormone secreation. Science. 1979;205:823-825.
41. Tataryn IV, Meldrum DR, Lu KH, Frumar AM, Judd HL. LH, FSH and skin temperaure during the menopausal hot flash. J Clin Endocrinol Metab. 1979;49:152-154.
42. Casper RF, Yen SS. Menopausal flushes: Effect of pituitary gonadotropin desensitization by a potent luteinizing hormone-releasing factor agonist. J Clin Endocrinol Metab. 1981;53:1056-1058.
43. Menon V, Edwards RL, Lynch SS, Butt WR. Luteinizing hormone releasing hormone analogue in treatment of hypergonadotrophic amenorrhoea. Br J Obstet Gynaecol. 1983;90:539-542.
44. Mulley G, Mitchell JR, Tattersall RB. Hot flushes after hypophysectomy. BMJ. 1977;2:1062.
45. Meldrum DR, Erlik Y, Lu JK, Judd HL. Objectively recorded hot flushes in patients with pituitary insufficiency. J Clin Endocrinol Metab. 1981;52:684-688.
46. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol. 1999;181:66-70.
47. Kronenberg F, Downey JA. Thermoregulatory physiology of menopausal hot flashes: A review. Can J Physiol Pharmacol. 1987;65:1312-1324.
48. Rosenberg J, Larsen SH. Hypothesis: Pathogenesis of postmenopausal hot flush. Med Hypotheses. 1991;35:349-350.
49. Wehrenberg WB, Wardlaw SL, Frantz AG, Ferin M. Beta-endorphin in hypophyseal portal blood: Variations throughout the menstrual cycle. Endocrinology. 1982;111:879-881.
50. Wardlaw SL, Wehrenberg WB, Ferin M, Antunes JL, Frantz AG. Effect of sex steroids on beta-endorphin in hypophyseal portal blood. J Clin Endocrinol Metab. 1982;55:877-881.
51. Gonzales GF, Carrillo C. Blood serotonin levels in postmenopausal women: Effects of age and serum oestradiol levels. Maturitas. 1993;17:23-29.
52. Blum I, Vered Y, Lifshitz A, et al. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women. Isr J Med Sci. 1996;32:1158-1162.
53. Fink G, Sumner BE. Oestrogen and mental state [letter]. Nature. 1996;383:306.
54. Berendsen HH. The role of serotonin in hot flushes. Maturitas. 2000;36:155-164.
55. Loprinzi CL, Goldberg RM, O'Fallon JR, et al. Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol. 1994;151:634-636.
56. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331:347-352.
57. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16:495-500.
58. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol. 2000;18:1068-1074.
59. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet. 2000;356:2059-2063.
60. Castelo-Branco C, Figueras F, Sanjuan A, et al. Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: Benefits to bone and analysis of factors associated with discontinuation. Menopause. Winter 1999;6:307-311.
61. Regan MM, Emond SK, Attardo MJ, Parker RA, Greenspan SL. Why do older women discontinue hormone replacement therapy? J Womens Health Gend Based Med. 2001;10:343-350.
62. Reynolds RF, Obermeyer CM, Walker AM, Guilbert D. Side effects and sociobehavioral factors associated with the discontinuation of hormone therapy in a Massachusetts health maintenance organization. Menopause. May-June 2001;8:189-199.
63. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal estrogen/progestin interventions trial. Obstet Gynecol. 1998;92:982-988.
64. Loprinzi CL, Barton D. Estrogen deficiency: In search of symptom control and sexuality [editorial]. J Natl Cancer Inst. 2000;92:1028-1029.
65. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively. J Clin Oncol. 1999;17:1482-1487.
66. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000;6:2028-2036.
67. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: A systematic review and quantitative assessment of risk. J Clin Oncol. 2001;19:2357-2363.
68. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93:754-762.
69. Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998;82:1784-1788.
70. Bullock JL, Massey FM, Gambrell RD Jr. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol. 1975;46:165-168.
71. Morrison JC, Martin DC, Blair RA, et al. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol. 1980;138:99-104.
72. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol. 1999;94:225-228,
73. Crombie C, Raghavan D, Page J, et al. Phase II study of megestrol acetate for metastatic carcinoma of the prostate. Br J Urol. 1987;59:443-446.
74. Dixon AR, Jackson L, Chan S, Haybittle J, Blamey RW. A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer. Br J Cancer. 1992;66:402-404.
75. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women: Report of seven cases and review of the literature. Cancer. 1997;79:320-327.
76. Foster GV, Zacur HA, Rock JA. Hot flashes in postmenopausal women ameliorated by danazol. Fertil Steril. 1985;43:401-404.
77. Simon J, Klaiber E, Wiita B, Bowen A, Yang HM. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause. Summer 1999;6:138-146.
78. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol. 1995;85:529-537.
79. Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998;105:904-911.
80. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: A multicenter, double-blind, randomized, placebo-controlled study [published correction appears in Menopause. 2000;7:422]. Menopause. 2000;7:236-242.
81. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: A pilot study. Menopause. 2000;7:105-111.
82. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes [published correction appears in Obstet Gynecol. 2001;98:702]. Obstet Gynecol. 1998;91:6-11.
83. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: A randomized, controlled clinical trial. J Clin Oncol. 2002;20:1449-1455.
84. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: A critical review of the literature. J Nutr. 2001; 131(11, suppl):3095S-3108S.
85. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998;16:2377-2381.
86. Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol. 1999;162:98-102.
87. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20:1578-1583.
88. Steams V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol. 2000;11:17-22.
89. Guttuso TJ Jr. Gabapentin's effects on hot flashes and hypothermia. Neurology. 2000;54:2161-2163.
90. Loprinzi CL, Barton DL, Sloan JA, et al. Pilot evaluation of gabapentin for alleviation of hot flashes [abstract]. Program Proc Am Soc Clin Oncol. 2002;21:362a. Abstract 1444.
91. Thummala AR, Griggs J, Rosenblatt J, et al. Pilot study using gabapentin on tamoxifen-induced hot flashes in women with breast cancer [abstract]. Program Proc Am Soc Clin Oncol. 2002;21:362a. Abstract 1445.
92. Melis GB, Gambacciani M, Cagnacci A, Paoletti AM, Mais V, Fioretti P. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol. 1988;72:688-692.
93. Wesel S, Bourguignon RP, Bosuma WB. Veralipride versus conjugated oestrogens: A double-blind study in the management of menopausal hot flushes. Curr Med Res Opin. 1984;8:696-700.
94. Vercellini P, Vendola N, Colombo A, Passadore C, Trespidi L, Crosignani PG. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest. 1992;34:102-104.
95. Verbeke K, Dhont M, Vandekerckhove D. Clinical and hormonal effects of long-term veralipride treatment in post-menopausal women. Maturitas. 1988;10:225-230.
96. David A, Don R, Tajchner G, Weissglas L. Veralipride: Alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol. 1988;158:1107-1115.
97. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes [published correction appears in J Clin Oncol. 1996;14:2411]. J Clin Oncol. 1994;12:155-158.
98. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000;132:788-793.
99. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001;19:2739-2745.
100. Duker EM, Kopanski L, Jarry H, Wuttke W. Effects of extracts from Cimicifuga racemosa on gonadotropin release in menopausal women and ovariectomized rats. Planta Med. 1991;57:420-424.
101. Kruse SO, Lohning A, Pauli GF, Winterhoff H, Nahrstedt A. Fukiic and piscidic acid esters from the rhizome of Cimicifuga racemosa and the in vitro estrogenic activity of fukinolic acid. Planta Med. 1999;65:763-764.
102. Liu Z, Yang Z, Zhu M, Huo J. Estrogenicity of black cohosh (Cimicifuga racemosa) and its effect on estrogen receptor level in human breast cancer MCF-7 cells [in Chinese]. Wei Sheng Yan Jiu. 2001;30:77-80.
103. Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G. Antiestrogenic activities of Cimicifuga racemosa extracts. J Steroid Biochem Mol Biol. 2002;80:125-130.
104. Liu J, Burdette JE, Xu H, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem. 2001;49:2472-2479.
105. Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats. Maturitas. 1996;25:149-153.
106. Davis SR, Briganti EM, Chen RQ, Dalais FS, Bailey M, Burger HG. The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women: A randomised controlled trial. Med J Aust. 2001;174:68-71.
107. Lebherz TB, French L. Nonhormonal treatment of the menopausal syndrome: A double-blind evaluation of an autonomic system stabilizer. Obstet Gynecol. 1969;33:795-799.
108. Bergmans MG, Merkus JM, Corbey RS, Schellekens LA, Ubachs JM. Effect of Bellergal Retard on climacteric complaints: A double-blind, placebo-controlled study. Maturitas. 1987;9:227-234.
109. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: Evaluation by ambulatory monitoring. Am J Obstet Gynecol. 1992;167:436-439.
110. Wijma K, Melin A, Nedstrand E, Hammar M. Treatment of menopausal symptoms with applied relaxation: A pilot study. J Behav Ther Exp Psychiatry. 1997;28:251-261.
111. Ivarsson T, Spetz AC, Hammar M. Physical exercise and vasomotor symptoms in postmenopausal women. Maturitas. 1998;29:139-146.
112. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. J Natl Cancer Inst. 2000;92:1054-1064.